Movement Alert｜Akeso Bio Rises 4.38% in Regular Trading, Innovative Drug Payment Reform Continues to Catalyze Amid Sector-Wide Strength

Market Focus07-10

On July 10, Akeso Bio rose 4.38% in regular trading, trading at HK$99.1/share, with turnover of HK$270 million.

On the news front, innovative drug payment reform continues to serve as a catalyst. The National Healthcare Security Administration previously released preliminary review results for the medical insurance directory, with the dual-track \"medical insurance + commercial insurance\" negotiation entering substantive implementation. New mechanisms including a pre-application system and 8-year price protection are simultaneously being rolled out, providing stable policy expectations for innovative drug commercialization. All indications of Akeso Bio's five self-developed new drugs have been included in the national medical insurance, and its new drug Qiyoukang has completed its first nationwide shipment, expected to accelerate market penetration.

Within the Biotechnology sector, the overall sector showed strength. Among individual stocks, REMEGEN up 5.06%, INNOVENT BIO up 4.11%, PEGBIO CO-B up 34.54%, 3SBIO up 2.06%, BEIGENE up 2.03%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1105493835?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-10 10:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1105493835","market":"us","top_or_hot":-1,"title":"Movement Alert｜Akeso Bio Rises 4.38% in Regular Trading, Innovative Drug Payment Reform Continues to Catalyze Amid Sector-Wide Strength","media":"Market Focus","content":"<p><p>On July 10, Akeso Bio rose 4.38% in regular trading, trading at HK$99.1/share, with turnover of HK$270 million.</p><p>On the news front, innovative drug payment reform continues to serve as a catalyst. The National Healthcare Security Administration previously released preliminary review results for the medical insurance directory, with the dual-track \\\"medical insurance + commercial insurance\\\" negotiation entering substantive implementation. New mechanisms including a pre-application system and 8-year price protection are simultaneously being rolled out, providing stable policy expectations for innovative drug commercialization. All indications of Akeso Bio's five self-developed new drugs have been included in the national medical insurance, and its new drug Qiyoukang has completed its first nationwide shipment, expected to accelerate market penetration.</p><p>Within the Biotechnology sector, the overall sector showed strength. Among individual stocks, REMEGEN up 5.06%, INNOVENT BIO up 4.11%, PEGBIO CO-B up 34.54%, 3SBIO up 2.06%, BEIGENE up 2.03%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Akeso Bio Rises 4.38% in Regular Trading, Innovative Drug Payment Reform Continues to Catalyze Amid Sector-Wide Strength</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Akeso Bio Rises 4.38% in Regular Trading, Innovative Drug Payment Reform Continues to Catalyze Amid Sector-Wide Strength\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-10 10:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 10, Akeso Bio rose 4.38% in regular trading, trading at HK$99.1/share, with turnover of HK$270 million.</p><p>On the news front, innovative drug payment reform continues to serve as a catalyst. The National Healthcare Security Administration previously released preliminary review results for the medical insurance directory, with the dual-track \\\"medical insurance + commercial insurance\\\" negotiation entering substantive implementation. New mechanisms including a pre-application system and 8-year price protection are simultaneously being rolled out, providing stable policy expectations for innovative drug commercialization. All indications of Akeso Bio's five self-developed new drugs have been included in the national medical insurance, and its new drug Qiyoukang has completed its first nationwide shipment, expected to accelerate market penetration.</p><p>Within the Biotechnology sector, the overall sector showed strength. Among individual stocks, REMEGEN up 5.06%, INNOVENT BIO up 4.11%, PEGBIO CO-B up 34.54%, 3SBIO up 2.06%, BEIGENE up 2.03%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"","article_id":"1105493835","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1105493835","pubTimestamp":1783649248,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 10, Akeso Bio rose 4.38% in regular trading, trading at HK$99.1/share, with turnover of HK$270 million.On the news front, innovative drug payment reform continues to serve as a catalyst. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09926":"康方生物"},"translate_title":"走势提醒|Akeso Bio常规交易上涨4.38%，创新药支付改革持续催化板块走强","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"On July 10, Akeso Bio rose 4.38% in regular trading, trading at HK$99.1/share, with turnover of HK$270 million.On the news front, innovative drug payment reform continues to serve as a catalyst. The National Healthcare Security Administration previously released preliminary review results for the medical insurance directory, with the dual-track \\\"medical insurance + commercial insurance\\\" negotiation entering substantive implementation. New mechanisms including a pre-application system and 8-year price protection are simultaneously being rolled out, providing stable policy expectations for innovative drug commercialization. All indications of Akeso Bio's five self-developed new drugs have been included in the national medical insurance, and its new drug Qiyoukang has completed its first nationwide shipment, expected to accelerate market penetration.Within the Biotechnology sector, the overall sector showed strength. Among individual stocks, REMEGEN up 5.06%, INNOVENT BIO up 4.11%, PEGBIO CO-B up 34.54%, 3SBIO up 2.06%, BEIGENE up 2.03%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1105493835","isCrawlerRequest":true}